Importing medicines into the European Union is a complex and highly regulated process
The process of importing medicines into the European Union (EU) is designed to ensure that all pharmaceutical products entering the market are safe, effective and of high quality.
Regulations and legislation on importing medicines
The import of medicines into the EU is governed by a strict regulatory framework to protect public health. Key laws and guidelines include:
Directive 2001/83/EC
Directive 2001/83/EC establishes a Community code on medicinal products for human use and is the basis for pharmaceutical regulation in the EU. It defines the requirements for the authorisation, manufacture, marketing and monitoring of medicines.
Good Manufacturing Practices (GMP)
Good manufacturing practices (GMP) are standards that ensure that medicines are consistently manufactured and controlled according to quality standards. Manufacturers of medicines outside the EU must comply with GMP to export their products to the EU.
Certificates of conformity
The EU requires imported medicines to have a Certificate of Conformity with the European Pharmacopoeia Monographs (EPC). This certificate confirms that the medicine meets the quality standards of the European Pharmacopoeia.
Import authorization for medicines
To import medicines into the EU, an import authorization must be obtained. This authorization is issued by the European Medicines Agency (EMA) or by the competent national authorities of the EU member states.
The requirements for obtaining this authorization include:
- Risk assessment: Medicines must undergo a rigorous assessment of safety, efficacy and quality. This assessment includes clinical trials, stability studies and analysis of active ingredients.
- Good Distribution Practices (GDP): Importers must follow Good Distribution Practices to ensure that medicines are handled and stored properly during transport and distribution.
- Inspections and audits: Regulatory authorities may conduct inspections and audits of manufacturing and distribution facilities to ensure compliance with GMP and GDP.
Required documentation for importing medicines
Importing medicines into the EU requires extensive documentation to ensure traceability and regulatory compliance. Some of the key documents include:
- Certificate of analysis: This certificate provides detailed information about the composition and quality testing of the medicine.
- Certificate of Good Manufacturing Practice (GMP): Issued by the regulatory authority of the country of origin, this certificate confirms that the medicine is manufactured according to GMP.
- Technical dossier: A complete technical dossier that includes data about the manufacturing, quality control, stability and clinical studies of the medicine.
- Declaration of conformity: A declaration that the medicine complies with all applicable EU regulations and guidelines.
Quality and safety controls
The EU implements strict quality and safety controls for imported medicines:
Batch release tests
Each batch of imported medicines must undergo release tests carried out by an authorised laboratory in the EU before they can be placed on the market. These tests verify that the medicine meets quality specifications.
Pharmacovigilance
Importers must implement pharmacovigilance systems to monitor the safety of the medicine once it is on the market. This includes collecting and evaluating data on adverse effects and implementing corrective measures if necessary.
Product recalls
In the event that quality or safety problems are detected, importers must have procedures in place for the rapid and efficient withdrawal of products from the market.
Customs and logistics aspects
Importing medicines also involves complying with customs and logistics procedures:
- Tariff classification: Medicines must be properly classified according to the Harmonized System (HS) of commodity coding to determine applicable tariffs and other taxes.
- Import licenses: Some medicines may require specific import licenses in addition to the general authorization.
- Storage and transportation conditions: Medicines must be transported and stored under controlled conditions to maintain their stability and efficacy. This may include temperature and humidity control, as well as protection from light and contamination.
- Customs clearance: The customs clearance process involves submitting all required documents and complying with EU customs regulations. It is essential to work with experienced customs agents to facilitate this process.
Brexit impact
Brexit has introduced significant changes to the import of medicines into the EU from the UK. Companies must be aware of the new regulations and additional requirements that apply to pharmaceutical products crossing this new border.
New certification requirements
The UK is no longer part of the EU regulatory system, meaning that certificates and authorisations issued by UK authorities are no longer valid in the EU. Importers must obtain the necessary authorisations and certifications from EU regulatory authorities.
Additional customs requirements
Imports from the UK are now subject to customs controls and may face tariffs and other taxes. It is crucial to be prepared for these changes to avoid delays in the clearance of medicines.
Ethical and sustainability considerations
In addition to complying with regulations, companies importing medicines must consider ethical and sustainability aspects:
Ethics in the supply chain
Ensuring that all actors in the supply chain comply with ethical standards is essential. This includes fair working practices, respect for human rights and safe working conditions.
Environmental sustainability
Companies must adopt sustainable practices in the manufacture and transport of medicines to minimise environmental impact. This may include the use of recyclable materials, waste reduction and optimisation of transport routes to reduce carbon emissions.
Contact us if you need the services of an importing laboratory, since according to current pharmaceutical legislation, a finished product must be released by a laboratory in European territory, prior to being placed on the market in any EU country.
